N-ethyl-leucine | 64991-32-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-ethyl-leucine
• 英文别名: N-Aethyl-leucin；α-Aethylamino-isocapronsaeure；Inakt. α-Aethylamino-isocapronsaeure；N-Aethyl-dl-leucin；Ethyl DL-leucine；2-(ethylamino)-4-methylpentanoic acid
• CAS: 64991-32-8
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: OLTRFLJKPXPCCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  乙胺 、 alkaline earth salt of/the/ methylsulfuric acid 在 水 作用下， 生成 N-ethyl-leucine
  参考文献：
  名称：

  Preparation of Some N-Substituted Amino Acid Analogs

  摘要：

  DOI：

  10.1021/ja01174a511

文献信息

• ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7)
  申请人：Morphic Therapeutic, Inc.

  公开号：US20190315692A1

  公开（公告）日：2019-10-17

  Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

  揭示了α4β7整合素的小分子拮抗剂，以及使用它们治疗多种特定疾病或病况的方法。
• [EN] NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY<br/>[FR] COMPOSITIONS DE NANOMATÉRIAU, SYNTHÈSE ET ASSEMBLAGE
  申请人：RHODE ISLAND HOSPITAL

  公开号：WO2016081522A1

  公开（公告）日：2016-05-26

  Compositions or an assembly of a series of biomimetic compounds include chemical structures that mimic or structurally resemble a nucleic acid base pair. Complexes of nanotubes and agents are useful to deliver agents into the cells or bodily tissues of individuals for therapeutic and diagnostic purposes. Exemplary compounds include those of Formula (I), (III), (V) or (VII), or of Formula (II), (IV), (VI) or (VIII).

  一系列仿生化合物的组成或装配包括模拟或在结构上类似于核酸碱基对的化学结构。纳米管和试剂的复合物可用于将试剂输送到个体的细胞或身体组织中，用于治疗和诊断目的。示例化合物包括Formula (I)、(III)、(V)或(VII)的化合物，或Formula (II)、(IV)、(VI)或(VIII)的化合物。
• [EN] SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS<br/>[FR] INHIBITEURS DES CANAUX DE CALCIUM DE PEPTIDYLAMINE SUBSTITUEE
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1998054123A1

  公开（公告）日：1998-12-03

  (EN) The present invention provides compounds that block calcium channels having Formula (I). The present invention also provides methods of using the compounds of Formula (I) to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula (I).(FR) L'invention concerne des composés inhibiteurs des canaux de calcium et représentés par la formule (I). Elle concerne également des procédés servant à mettre en application ces composés afin de traiter les attaques, l'ischémie cérébrale, le traumatisme crânien ou l'épilepsie, ainsi que des compositions pharmaceutiques contenant ces composés.

  (中) 本发明提供了具有公式（I）的阻断钙通道的化合物。本发明还提供了使用公式（I）的化合物治疗中风、脑缺血、头部创伤或癫痫的方法，以及含有公式（I）的制药组合物。
• Urea derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070093501A1

  公开（公告）日：2007-04-26

  The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R 1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is —C(O)—, —S(O)—, or —S(O) 2 —; W is —N(R 2 )—, —O—, or a bond (wherein R 2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is —C(O)—, —S(O)—, or —S(O) 2 —; Z is a bond, a chain hydrocarbon group which may be substituted, or —N═; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2] , are each independently a single bond or a double bond; provided that R 1 may be bonded to R 2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R 2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

  本发明提供一种尿素衍生物或其盐，其作为治疗血栓症的治疗剂是有用的。该衍生物由公式（I）表示：其中，Cy是芳香族羟基烃基或芳香族杂环基，可以被取代；R1是氢原子或可以被取代的碳氢基团；V是-C（O）-，-S（O）-或-S（O）2-；W是-N（R2）-，-O-或键（其中R2是氢原子或可以被取代的碳氢基团）；X是可以被取代的烷基；Y是-C（O）-，-S（O）-或-S（O）2-；Z是键，可以被取代的链烃基团或-N═；环A是非芳香族含氮杂环环，可以被取代；环B是含氮杂环环，可以被取代；而[化学式2]都是单键或双键；但是，R1可以与R2连接形成非芳香族含氮杂环环，而R2可以与X的取代基连接形成可以被取代的非芳香族含氮杂环环。
• Derivatives of 18Beta-Glycyrrhetinic Acid
  申请人：Ward Simon

  公开号：US20090076032A1

  公开（公告）日：2009-03-19

  The present invention relates to novel derivatives of 18β-glycyrrhetinic acid and methods of synthesising the derivatives. Also included within the scope of the present invention are pharmaceutical compositions comprising the derivatives of the present invention and medical uses of the derivatives, including their use in inhibiting enzymes such as retinol dehydrogenases. The present invention also relates to methods of treating diseases, such as hyperproliferative diseases, neoplasms, cancers and photoageing.

  本发明涉及18β-甘草酸的新衍生物及其合成方法。本发明的范围还包括包含本发明衍生物的制药组合物以及本发明衍生物的医学用途，包括它们在抑制酶如视黄醇脱氢酶中的使用。本发明还涉及治疗疾病的方法，例如增生性疾病、肿瘤、癌症和光老化。